BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11123981)

  • 1. Synthesis and structure-activity relationships of chiral allosteric modifiers of hemoglobin.
    Phelps Grella M; Danso-Danquah R; Safo MK; Joshi GS; Kister J; Marden M; Hoffman SJ; Abraham DJ
    J Med Chem; 2000 Dec; 43(25):4726-37. PubMed ID: 11123981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and X-ray studies of chiral allosteric modifiers of hemoglobin.
    Youssef AM; Safo MK; Danso-Danquah R; Joshi GS; Kister J; Marden MC; Abraham DJ
    J Med Chem; 2002 Mar; 45(6):1184-95. PubMed ID: 11881987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector.
    Safo MK; Moure CM; Burnett JC; Joshi GS; Abraham DJ
    Protein Sci; 2001 May; 10(5):951-7. PubMed ID: 11316875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
    Randad RS; Mahran MA; Mehanna AS; Abraham DJ
    J Med Chem; 1991 Feb; 34(2):752-7. PubMed ID: 1995897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats.
    Abraham DJ; Wireko FC; Randad RS; Poyart C; Kister J; Bohn B; Liard JF; Kunert MP
    Biochemistry; 1992 Sep; 31(38):9141-9. PubMed ID: 1390701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. X-ray crystallographic analyses of symmetrical allosteric effectors of hemoglobin: compounds designed to link primary and secondary binding sites.
    Safo MK; Boyiri T; Burnett JC; Danso-Danquah R; Moure CM; Joshi GS; Abraham DJ
    Acta Crystallogr D Biol Crystallogr; 2002 Apr; 58(Pt 4):634-44. PubMed ID: 11914488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RSR13, a synthetic allosteric modifier of hemoglobin, improves myocardial recovery following hypothermic cardiopulmonary bypass.
    Kilgore KS; Shwartz CF; Gallagher MA; Steffen RP; Mosca RS; Bolling SF
    Circulation; 1999 Nov; 100(19 Suppl):II351-6. PubMed ID: 10567328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Prodrugs as Drug Candidates for the Treatment of Ischemic Disorders: Insights into NO-Releasing Prodrug Biotransformation and Hemoglobin-NO Biochemistry.
    Xu GG; Deshpande TM; Ghatge MS; Mehta AY; Omar AS; Ahmed MH; Venitz J; Abdulmalik O; Zhang Y; Safo MK
    Biochemistry; 2015 Dec; 54(49):7178-92. PubMed ID: 26582149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dose-dependent effect of RSR13, a synthetic allosteric modifier of hemoglobin, on physiological parameters and brain tissue oxygenation in rats.
    Grinberg OY; Miyake M; Hou H; Steffen RP; Swartz HM
    Adv Exp Med Biol; 2003; 530():287-96. PubMed ID: 14562725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13.
    Amorino GP; Lee H; Holburn GE; Paschal CB; Hercules SK; Shyr Y; Steffen RP; Choy H
    Radiat Res; 2001 Sep; 156(3):294-300. PubMed ID: 11500138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSAII and SCCVII tumours in C3H mice.
    Khandelwal SR; Kavanagh BD; Lin PS; Truong QT; Lu J; Abraham DJ; Schmidt-Ullrich RK
    Br J Cancer; 1999 Feb; 79(5-6):814-20. PubMed ID: 10070874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of RSR13, a synthetic allosteric modifier of hemoglobin, alone and in combination with dizocilpine, on outcome from transient focal cerebral ischemia in the rat.
    Sarraf-Yazdi S; Sheng H; Grocott HP; Bart RD; Pearlstein RD; Steffen RP; Warner DS
    Brain Res; 1999 May; 826(2):172-80. PubMed ID: 10224294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of RSR13, a synthetic allosteric modifier of hemoglobin, on brain tissue pO2 (measured by EPR oximetry) following severe hemorrhagic shock in rats.
    Miyake M; Grinberg OY; Hou H; Steffen RP; Elkadi H; Swartz HM
    Adv Exp Med Biol; 2003; 530():319-29. PubMed ID: 14562728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric modification of hemoglobin by RSR13 as a therapeutic strategy.
    Steffen RP; Liard JF; Gerber MJ; Hoffman SJ
    Adv Exp Med Biol; 2003; 530():249-59. PubMed ID: 14562722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric modification of oxygen delivery by hemoglobin.
    Wahr JA; Gerber M; Venitz J; Baliga N
    Anesth Analg; 2001 Mar; 92(3):615-20. PubMed ID: 11226087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RSR13, a synthetic modifier of hemoglobin-oxygen affinity, enhances the recovery of stunned myocardium in anesthetized dogs.
    Pagel PS; Hettrick DA; Montgomery MW; Kersten JR; Steffen RP; Warltier DC
    J Pharmacol Exp Ther; 1998 Apr; 285(1):1-8. PubMed ID: 9535987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme.
    Kleinberg L; Grossman SA; Piantadosi S; Pearlman J; Engelhard H; Lesser G; Ruffer J; Gerber M
    J Clin Oncol; 1999 Aug; 17(8):2593-603. PubMed ID: 10561327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation.
    Khandelwal SR; Randad RS; Lin PS; Meng H; Pittman RN; Kontos HA; Choi SC; Abraham DJ; Schmidt-Ullrich R
    Am J Physiol; 1993 Oct; 265(4 Pt 2):H1450-3. PubMed ID: 8238433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preservation of canine myocardial high-energy phosphates during low-flow ischemia with modification of hemoglobin-oxygen affinity.
    Weiss RG; Mejia MA; Kass DA; DiPaula AF; Becker LC; Gerstenblith G; Chacko VP
    J Clin Invest; 1999 Mar; 103(5):739-46. PubMed ID: 10074492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin.
    Omar AM; Mahran MA; Ghatge MS; Bamane FH; Ahmed MH; El-Araby ME; Abdulmalik O; Safo MK
    Molecules; 2016 Aug; 21(8):. PubMed ID: 27529207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.